Therefore, in the current study, we investigated whether CHEK2 H371Y mutation carriers are more likely to respond to neoadjuvant chemotherapy in terms of pathologic complete response (pCR) in a large cohort of 2334 breast cancer patients who received neoadjuvant chemotherapy and further explored the association between CHEK2 H371Y mutation status and distant recurrence-free survival (DRFS). This evidence concerns the gene CHEK2 and breast carcinoma.